Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide for Maintenance Therapy of ANCA Associated Vasculitis
NCT04737343Unknown
- Sponsor
- Chinese SLE Treatment And Research Group
- Start
- Jun 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of leflunomide in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) (2 arms), sponsored by Chinese SLE Treatment And Research Group. Primary endpoint: Percentage of patients with major relapse at 18 months. Status: unknown.
02
Drugs
leflunomide
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT04737343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04737343.